文献速递肾小球疾病遗传性与小管间质肾病

单基因囊性肾病及纤毛病胚胎植入前遗传学检测的科学现状与伦理考量

State of the Science and Ethical Considerations for Preimplantation Genetic Testing for Monogenic Cystic Kidney Diseases and Ciliopathies.
PubMed 文献 · J Am Soc Nephrol · 2023-10-26

该综述阐述单基因多囊肾病(PKD)及纤毛病相关基因缺陷可致囊肿形成和肾功能衰竭,胚胎植入前遗传学检测(PGT-M)通过体外受精后检测胚胎并选择性移植不携带致病变异的胚胎,使准父母避免传递遗传病。已有文献支持PGT-M在常染色体显性和隐性PKD中的成功应用,但部分病例存在技术局限,且该技术涉及政府监管有限、知情同意流程不统一、技术误差、高成本与公平性、患病母亲妊娠风险及对后代影响等伦理问题。

要点

  • PGT-M可帮助单基因PKD家庭避免传递致病变异,已有常染色体显性和隐性PKD的成功文献支持。
  • 部分病例存在重要技术局限,其他单基因PKD及纤毛病缺乏现有文献报告。
  • PGT-M涉及政府监管有限、知情同意不统一、技术误差、高成本与公平性等伦理考量。

核心结论

  • PGT-M为单基因PKD及纤毛病家庭提供避免传递致病变异的选择,但需权衡技术局限与伦理问题。

研究设计与样本

  • 综述类文章,检索范围未在摘要中明确报告。

主要发现

  • 单基因PKD表型谱广泛,常涉及纤毛相关基因,导致液性囊肿和肾功能下降及衰竭。
  • PGT-M通过体外受精产生胚胎,检测后选择性移植不携带特定致病变异的胚胎。
  • 已有文献支持PGT-M在常染色体显性和隐性PKD中的成功,但部分病例存在重要技术局限。
  • 许多其他类型单基因PKD及纤毛病虽无现有文献报告,该技术仍可应用。

关键数值与推荐

  • 原文未报告具体推荐等级、剂量、阈值或数值标准。

临床怎么用

  • 原文未报告临床实践推荐。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is a broad phenotypic spectrum of monogenic polycystic kidney diseases (PKDs). These disorders often involve cilia-related genes and lead to the development of fluid-filled cysts and eventual kidney function decline and failure. Preimplantation genetic testing for monogenic (PGT-M) disorders has moved into the clinical realm. It allows prospective parents to avoid passing on heritable diseases to their children, including monogenic PKD. The PGT-M process involves embryo generation through in vitro fertilization, with subsequent testing of embryos and selective transfer of those that do not harbor the specific disease-causing variant(s). There is a growing body of literature supporting the success of PGT-M for autosomal-dominant and autosomal-recessive PKD, although with important technical limitations in some cases. This technology can be applied to many other types of monogenic PKD and ciliopathies despite the lack of existing reports in the literature. PGT-M for monogenic PKD, like other forms of assisted reproductive technology, raises important ethical questions. When considering PGT-M for kidney diseases, as well as the potential to avoid disease in future generations, there are regulatory and ethical considerations. These include limited government regulation and unstandardized consent processes, potential technical errors, high cost and equity concerns, risks associated with pregnancy for mothers with kidney disease, and the impact on all involved in the process, including the children who were made possible with this technology.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Thompson WS, Babayev SN, McGowan ML, et al. State of the Science and Ethical Considerations for Preimplantation Genetic Testing for Monogenic Cystic Kidney Diseases and Ciliopathies. J Am Soc Nephrol. 2023. PMID: 37882743. doi:10.1681/ASN.0000000000000253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。